Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Fate Therapeutics Inc (FATE) Stock: Soaring On Financing And EU Approval

Shares in Fate Therapeutics Inc (NASDAQ:FATE) have soared today, gaining over 10% and reaching as high as $3.18 during the session.

Why is Fate Soaring

Fate Therapeutics Inc (NASDAQ:FATE) announced on Tuesday that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors. The deal was led by Redmile Group LLC, facilitating a deal worth approximately $57 million prior to ordinary fees and associated expenses.

lab, laboratory, clinic, clinical, scientist, researching, research, chemist, medical, man, male, specialist, focus, chemistry, test, science

Pressmaster/Shutterstock.com

In the deal, Redmile has agreed to purchase 2,819,549 shares of non-voting Class A Preferred stock at $13.30 per share, with each share being convertible into five shares of common stock upon certain conditions. Based on the closing price of FATE on 11/21/16, the deal was an at-the money raise, which certainly bodes well for showing confidence in the stock by investors.

The remaining accredited investors, including company insiders, have agreed to purchase 7,236,837 shares of common stock at $2.66 per share, also at-the-money in relation to the closing price on 11/21/16.

The proceeds of the transaction will be used to advance the company’s pipeline of programmed cellular immunotherapies and for general purposes.

Orphan Approval In EU

The Twitter community also lit up the wires with information that the EU granted FATE Orphan Drug designation on 11/18/16 for its treatment in haematopoietic stem cell transplantation.

The company has not yet released the EU news and when it does, FATE may enjoy an additional bounce higher.

The 52-week range for FATE is $1.46 – $4.67 a share, with average volume being 157K shares per day. Investors appear to like the news, with FATE trading over 1.47 million shares on Tuesday.

The Fate of FATE

With cash in the bank, an Orphan Designation and closing a strong financing deal, Fate Therapeutics Inc (NASDAQ:FATE) appears to be on track to deliver some meaningful data in the coming months. Although thinly-traded, FATE is a stock worthy of being put on an investor’s radar.

We’ll keep an eye on FATE for our readers and apprise of any material details or changes in the strategic vision at FATE.

Follow Fate Therapeutics Inc (NASDAQ:FATE)
Trade (NASDAQ:FATE) Now!

About the Author:

Kenny Soulstring is an entrepreneurial visionary with a thirty year history developing and operating small to mid sized businesses. His experience in building a brand led to his interest in investing in small and emerging companies, and for the prior twenty years, his investments allow him to take part in new ventures without undertaking all of the legwork. Focused on finding compelling opportunities in the small cap sector, Soulstring enjoys the art of the build, watching a company develop from concept to maturity. His frequent contact with company management allows him to offer timely and relevant information, working to keep news fresh with a spicy commentary to match. Soulstring was raised in Miami Beach, Florida and plans to retire there when his hair turns fully gray.

Note: This article is written by Kenny Soulstring and was originally published at CNA Finance.

Loading Comments...